Page last updated: 2024-08-18

cyclohexanol and medroxyprogesterone acetate

cyclohexanol has been researched along with medroxyprogesterone acetate in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barton, D; Bearden, JD; Dakhil, SR; Fitch, TR; Kugler, JW; Levitt, R; Loprinzi, CL; Mailliard, JA; Nikcevich, DA; Sloan, JA; Tschetter, LK1
Bouchard, P; Irani, J; Mottet, N; Oba, R; Salomon, L1

Trials

2 trial(s) available for cyclohexanol and medroxyprogesterone acetate

ArticleYear
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-20, Volume: 24, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Hormonal; Cyclohexanols; Drug Therapy, Combination; Female; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride

2006
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Androgen Antagonists; Autonomic Agents; Cyclohexanols; Cyproterone Acetate; Double-Blind Method; Gonadotropin-Releasing Hormone; Hot Flashes; Humans; Male; Medroxyprogesterone Acetate; Prospective Studies; Prostatic Neoplasms; Treatment Outcome; Venlafaxine Hydrochloride

2010